Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Karla A. Henning"'
Autor:
Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, Natalie A. Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael D. Robbins, Adam D. Cohen, Kerry S. Campbell
Publikováno v:
OncoImmunology, Vol 6, Iss 9 (2017)
Elotuzumab is a humanized therapeutic monoclonal antibody directed to the surface glycoprotein SLAMF7 (CS1, CRACC, CD319), which is highly expressed on multiple myeloma (MM) tumor cells. Improved clinical outcomes have been observed following treatme
Externí odkaz:
https://doaj.org/article/e05a7c7070914bb0ac2df82d3517c889
Autor:
Edith A Perez, Andrew Luo, Anthony Lucas, Han K Kim, Paul D Ponath, Katelynn A McEachin, Karla A Henning, Shelley E Ackerman, Steven J Chapin, Michael N Alonso, Cecelia I Pearson, David Omstead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3dd5d80f575f46cfba2236317430d3dc
Autor:
Matthew Zhou, William Mallet, Romas Kudirka, Han K Kim, Justin Monnier, Chi-Ling Fu, Jennifer E Melrose, Hung Dao, Paul D Ponath, Katelynn A McEachin, David T Omstead, Cindy Kreder, Stefan Chun, Ying Yueh Lee, Rachel Grgich, Tracey J Lin, Joshua A Walker, Karla A Henning, Shelley E Ackerman, Diane Carrera, Steven J Chapin, Dowdy Jackson, Changshou Gao, Michael N Alonso
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/30e7900b97ae4dd8a324a8032d05c871
Autor:
Alan J. Korman, Mohan Srinivasan, Timothy Chen, Karla A. Henning, Michael Quigley, John J. Engelhardt, Mark J. Selby
PDF file - 102K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a78834acb42bbd09b0c532e9cc23c8a
https://doi.org/10.1158/2326-6066.22536218.v1
https://doi.org/10.1158/2326-6066.22536218.v1
Autor:
Alan J. Korman, Mohan Srinivasan, Timothy Chen, Karla A. Henning, Michael Quigley, John J. Engelhardt, Mark J. Selby
PDF file - 206K, Supplemental Figure S1. Equivalent binding of anti-CTLA-4 isotypes to cell surface CTLA-4. Supplemental Figure S2. Serum concentrations of anti-CTLA-4 isotypes in C57BL/6 mice. Supplemental Figure S3. Representative FACS plots for pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f18a019212133139aeaed992d67891
https://doi.org/10.1158/2326-6066.22536215
https://doi.org/10.1158/2326-6066.22536215
Autor:
Alan J. Korman, Mohan Srinivasan, Timothy Chen, Karla A. Henning, Michael Quigley, John J. Engelhardt, Mark J. Selby
Antitumor activity of CTLA-4 antibody blockade is thought to be mediated by interfering with the negative regulation of T-effector cell (Teff) function resulting from CTLA-4 engagement by B7-ligands. In addition, a role for CTLA-4 on regulatory T cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6011009163f523d370deaf09ace35c72
https://doi.org/10.1158/2326-6066.c.6548072
https://doi.org/10.1158/2326-6066.c.6548072
Autor:
Alan J. Korman, Mohan Srinivasan, Timothy Chen, Karla A. Henning, Michael Quigley, John J. Engelhardt, Mark J. Selby
PDF file - 94K, Supplemental Table S1. Binding affinities of anti-CTLA-4 isotypes to murine FcγR proteins as assessed by surface plasmon resonance. Supplemental Table S2. Summary of pharmacokinetic parameters of anti-CTLA4 isotypes following a singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9402efd30c653fdbc8ddf8b449235fcc
https://doi.org/10.1158/2326-6066.22536212.v1
https://doi.org/10.1158/2326-6066.22536212.v1
Autor:
Justin A. Kenkel, Fang Xiao, Po Y. Ho, Jess L. Nolin, Rishali K. Gadkari, Laughing Bear Torrez, David T. Omstead, Katelynn A. McEachin, Jason Ptacek, Rachel Grgich, Cecelia I. Pearson, Stefan Chun, Cindy L. Kreder, Karla A. Henning, Han K. Kim, Lu Xu, Steven J. Chapin, Michael N. Alonso, Shelley E. Ackerman
Publikováno v:
Cancer Research. 83:2964-2964
Tumor-associated macrophages (TAMs) are the largest immune cell population in many cancers and play a key role in establishing the immunosuppressive tumor microenvironment (TME) that enables tumor progression. However, TAMs are phenotypically plastic
Autor:
Lisa K. Blum, Cecelia I. Pearson, Laughing Bear Torrez Dulgeroff, Rishali Gadkari, Angela Luo, Andrew Luo, Jennifer E. Melrose, Jess L. Nolin, Hai Li, Arthur Lee, Matthew N. Zhou, Puneet Anand, Ganapathy Sarma, Karla A. Henning, Steven J. Chapin, Shelley E. Ackerman, Romas Kudirka, Yuyi Shen, Bruce Hug, Edith A. Perez, Marcin Kowanetz, Michael N. Alonso, Brian S. Safina, David Dornan, William G. Mallet
Publikováno v:
Cancer Research. 82:2911-2911
Introduction: Immune-stimulating antibody conjugates (ISACs) direct a TLR7/8 agonist into tumors through engagement of cell surface antigens to activate tumor-associated myeloid cells and initiate a broad innate and adaptive anti-tumor immune respons
Autor:
Justin A. Kenkel, Rishali Gadkari, Po Y. Ho, Lisa K. Blum, Romas Kudirka, Karla A. Henning, William G. Mallet, Jennifer E. Melrose, Ganapathy Sarma, Steven J. Chapin, Matthew Zhou, Suprit Deol, Cindy Kreder, Yuyi Shen, Bruce Hug, Puneet Anand, Arthur Lee, Hai Li, Shelley E. Ackerman, Brian S. Safina, David Dornan, Michael N. Alonso, Marcin Kowanetz
Publikováno v:
Cancer Research. 82:4252-4252
INTRODUCTION: Immune-stimulating antibody conjugates (ISACs) consist of tumor-targeting antibodies conjugated to immune stimulants and are designed to activate the innate and adaptive immune systems against tumor cells following systemic administrati